Faculty Information - Masashi Shimoda

（Last updated : 2021-09-17 15:55:54）

Masashi Shimoda
Department Kawasaki Medical School Kawasaki Medical School, Department of Diabetes, Endocrinology and Metabolism,

Position Assistant Professor

■ Publications

2016/02

Current Topics of SGLT2 inhibitors: Comparison of Appraisal and Working Condition between Major western Countries and Japan

■ Journal Articles

1.	2017/03	Temporal lobe epilepsy associated with GAD autoimmunity.
2.	2016/11	Association of GA/HbA1c ratio and cognitive impairment in subjects with type 2 diabetes mellitus.
3.	2016/11	Human serum albumin: Possible cause of insulin autoimmune syndrome.
4.	2016/09	Controversy about the relationship between sulfonylurea use and cardiovascular events and mortality.
5.	2016/09	Strawberry milk-like blood in a subject with diabetic lipemia: dramatic change to transparent color after insulin therapy.
6.	2016/08	Clinical effects of liraglutide are possibly influenced by hypertriglyceridemia and remaining pancreatic beta-cell function in subjects with type 2 diabetes mellitus.
7.	2016/07	Case of disseminated pyomyositis in poorly controlled type 2 diabetes mellitus with diabetic ketoacidosis.
8.	2016/06	Hamman's syndrome triggered by the onset of type 1 diabetes mellitus accompanied by diabetic ketoacidosis.
9.	2016/06	Promising Diabetes Therapy Based on the Molecular Mechanism for Glucose Toxicity: Usefulness of SGLT2 Inhibitors As Well As Incretin-Related Drugs.
10.	2016/05	Case of iliopsoas abscess that was markedly recovered after percutaneous and surgical drainage in a patient with poorly controlled type 2 diabetes.
11.	2016/03	Appropriate therapy for type 2 diabetes mellitus in view of pancreatic B-cell glucose toxicity: the earlier
12.	2016/03	Influence of atherosclerosis-related risk factors on serum hs-CRP levels in type 2 diabetic patients: Comparison of their influence between in obese and non-obese subjects.
13.	2016/02	Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic B-cells in obese type 2 diabetic db/db mice.
14.	2016/01	Ice cube tray-shaped insulin lipoatrophy throughout the abdomen in a subject with type 2 diabetes.
15.	2016	Seven-year Observational Study on the Association between Glycemic Control and the New Onset of Macroangiopathy in Japanese Subjects with Type 2 Diabetes
16.	2015/09	Combination of DPP-4 inhibitor and PPARr agonist exerts protective effects on pancreatic beta-cells in diabetic db/db mice through the augmentation of IRS-2 expression.
17.	2015/09	Pancreatic Inflammation Captured by Imaging Technology at the Onset of Fulminant Type 1 Diabetes.
18.	2015/08	Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study)
19.	2015/07	Pseudoaldosteronism induced by Yokukansan in an elderly Japanese type 2 diabetes mellitus patient with Alzheimer's disease.
20.	2015/06	Anti-hypertensive azelnidipine preserves insulin signaling and glucose uptake against oxidative stress in 3T3-L1 adipocytes
21.	2015/06	Low bilirubin levels are an independent risk factor for diabetic retinopathy and nephropathy in Japanese patients with type 2 diabetes.
22.	2015/05	Case of newly onset type 1 diabetes after highly active antiretroviral therapy against HIV infection.
23.	2015/05	Rapid onset of syndrome of inappropriate antidiuretic hormone secretion induced by duloxetine in an elderly type 2 diabetic patient with painful diabetic neuropathy.
24.	2015/01	Protective effects of pioglitazone and/or liraglutide on pancreatic B-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes
25.	2015	A case of disseminated pyomyositis in poorly controlled type 2 diabetes with diabetic ketoacidosis.
26.	2015	Case of iliopsoas abscess which was markedly recovered after percutaneous and surgical drainage in a subject with poorly controlled type 2 diabetes.
27.	2013/05	Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus.
28.	2013/02	Vildagliptin preserves the mass and function of pancreatic cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes.
29.	2012/02	Self-inducible secretion of glucagon-like peptide-1 (GLP-1) that allows MIN6 cells to maintain insulin secretion and insure cell survival.
30.	2011/05	The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes.
31.	2009/09	Gallbladder edema in type 1 diabetic patient due to delayed-type insulin allergy.
32.	2009/09	Gallbladder edema in type 1 diabetic patient due to delayed-type insulin allergy.
33.	2009/08	Molecular Analysis of db Gene-related Pancreatic beta Cell Dysfunction; Evidence for a Compensatory Mechanism Inhibiting Development of Diabetes in the db Gene Heterozygote.
34.	2009/08	Molecular Analysis of db Gene-related Pancreatic beta Cell Dysfunction; Evidence for a Compensatory Mechanism Inhibiting Development of Diabetes in the db Gene Heterozygote.
35.	2007/08	Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing.
36.	2007/08	Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing.
Display 5 items
Display all(36)

■ Presentations

1.	2015/11/21	Vascular GLP-1 receptor expression decreases in subjects with obesity （Poster notice，General）
2.	2015/09/17	Down-regulation of vascular GLP-1 receptor expression in subjects with obesity （Poster notice，General）
3.	2015/06/08	Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic beta-cells in obese type 2 diabetic db/db mice （Poster notice，General）
4.	2014/11/22	Protective effect of pioglitazone and liraglutide on B-cells with the progression of diabetic morbidity （Poster notice，General）
5.	2013/09/24	Molecular mechanism of protective effect by pioglitazone and/or liraglutide on beta cell damage with the progression of diabetic morbidity （Poster notice，General）
6.	2013/09/24	Pulsatile secretion of glucagon-like peptide-1(GLP-1) from pancreatic alpha cells: evidence for independent mechanism from intestinal GLP-1 secretion in rodents （Speech，General）
7.	2013/06/24	Molecular Mechanism of b-Cell Dysfunction in Obese Diabetic b/db Mice:Implication of the Islet Inflammation due to Residual Leptin Signal （Poster notice，General）
8.	2013/06/15	Cortisol-metabolizing systems in hepatocellular carcinoma and adjacent liver tissues （Poster notice，General）
9.	2012/11/17	Effects of growth hormone excess on cortisol metabolism and pituitary-adrenal axis （Poster notice，General）
10.	2012/06/11	Ablation of PDK1 in Vascular Endothelial Cells Diabetic Condition Deterio （Poster notice）
11.	2011/09/15	DPP-IV inhibitor vildagliptin increase the pancreatic b cell mass in non-diabetic mice by directly regulating cell kinetics （Poster notice，General）
12.	2011/09/14	The islet Inflammation and fibrosis precedes structural and functional abnormalities of the pancreatic islets in obese diabetic db/db mice （Poster notice，General）
13.	2011/07/23	Antioxidative effect of azelnidpine ameliorates insulin sensitivity of 3T3-L1 adipocytes （Poster notice，General）
14.	2011/07/23	Molecular mechanism of vildagliptin effect on pancreatic beta cell preservation （Poster notice，General）
15.	2011/06/25	Ablation of PDK1 in vascular endothelial cells deteriorates systemic insulin sensitivity and angiogenesis of skeletal muscles in STZ-induced hyperglycemic mice （Poster notice）
16.	2010/09/21	Molecular mechanism of DPP-IV inhibitor vildagliptin effect on pancreatic beta cell preservation in diabetic mice: evidence for antioxidative and ER stress mechanism （Poster notice，General）
17.	2010/09/21	The fibrosis in pancreatic islets at an early stage of life involves in diabetes development in obese diabetic db/db mice （Poster notice）
18.	2010/06	Molecular Mechanism of Antihypertensive Azelnidipine-Induced Augmention of Insulin Sensitivity: Evidence for Antioxidative Effect on Insulin Target 3T3-L1 Cells （Poster notice）
19.	2009/11	The strict control of hyperglycemia in the early stage of diabetes is important in maintaining long-term glycemic control -from a longitudinal analysis for 8 years- （Speech，General）
20.	2009/10/01	Comparative analysis of db and ob gene-related pancreatic β cell function; evidence for a compensatory mechanism of cell protection in ob/ob mice （Poster notice，General）
21.	2009/09	The once-daily human GLP-1 analogue liraglutide increases the beta cell mass in normoglycaemic mice by directly accelerating cell differentiation and proliferation （Speech，General）
22.	2009/06	Ablation of Vascular Endothelial PDK1 in Diabetic db/db Mice Further Deteriorates Insulin Sensitivity through Defects of Angiogenensis in Skeletal Muscle and Adipose Tissue （Poster notice，General）
23.	2008/09/10	The once-daily human GLP-1 analogue liraglutide preserves pancreatic beta cells in diabetic db/db mice through both acute and chronic action mechanisms. （Poster notice，General）
24.	2008/09/09	Molecular mechanism of diet effect on pancreatic beta cell preservation in diabetic db/db mice: evidence for anti-oxidative stress mechanism. （Speech，General）
25.	2008/06/09	Molecular mechanism for proliferative effect of the once-daily human GLP-1 analog liraglutide on the pancreatic b -cells in diabetic db/db mice: evidence for anti-oxidative stress mechanism. （Poster notice，General）
26.	2007/10	Analysis of risk factors involved in diabetic macroangiopathy: evidence for different risk indicators between aged and non-aged patients （Speech，General）
27.	2007/10	Effect of visceral fat accumulation on diabetic macroangiopathy: lack of evidence for the current cut-off point to predict macrovascular events （Speech，General）
28.	2006/12	Clinical significance of intra-abdominal obesity on macrovascular complications in patients with type 2 diabetes.
29.	2006/12	Pioglitazone, but not metformin, increases plasma HDL-chol level in type 2 diabetic patients treated with insulin
30.	2005/11	Clinical Courses in Type 2 Diabetic Patients Analyzed from 5 Years, Consecutive Data.
31.	2005/09	Pioglitazone modifies not only distribution but also density of adipose tissue in type 2 diabetic patienbts.
32.	2004/11	Relation between psoas muscle area and abdominal adipocity measured by computed tomography in patients with type 2 diabetes mellitus.
Display 5 items
Display all(32)

■ Professional Organizations

1.	2003/12	The Japanese Society of Internal Medicine
2.	2005/05～	Japan Diabetes Society